KEY FINDINGS: Approximately 30% of infants with FoCHI showed early spontaneous glycemic improvement. Although surgery remains the standard curative treatment, carefully selected infants with favourable early glucose control may be considered for conservative management, particularly when pancreatic head surgery carries substantial risk. The predictive score is exploratory and requires further validation. Close glucose monitoring and specialist assessment remain essential before deferring surgery.
BACKGROUND: Congenital hyperinsulinism (CHI) is the most common genetic cause of hypoglycemia in infants. In focal congenital hyperinsulinism (FoCHI), excessive insulin secretion originates from a localized pancreatic lesion that can often be surgically removed. However, surgery, particularly involving the pancreatic head, carries a risk of postoperative complications.
DETAILS: Researchers retrospectively reviewed 39 patients treated at a single referral centre. Patients were classified according to whether continuous gastric tube feeding was required to maintain glucose control: 12 patients (30.8%) were in the no-tube-feeding (NTF) group and 27 (69.2%) in the tube-feeding (TF) group. The NTF group had later diagnosis (P = .022) and less severe initial hypoglycemia (P = .003). An exploratory predictive score for early disease evolution demonstrated 97% specificity.
Four of the 12 patients in the NTF group experienced spontaneous resolution of hypoglycemia before 6 years of age and did not require surgery. Surgery was curative in 96.3% of the TF group and 100% of the NTF group. Long-term complications occurred in 8.6% and 0%, respectively, and consisted exclusively of exocrine pancreatic insufficiency. This complication occurred only after pancreatic head surgery, affecting 15.8% of patients undergoing that procedure.
Copyright © Skyscape. All rights reserved.
Source: Arnoux, J. B., Mayer, C., Jhaouat, I., et al. Focal congenital hyperinsulinism: spontaneous glycemic improvement before surgery. The Journal of Clinical Endocrinology & Metabolism. 2026; 111(11): 3032-3041. Published: November 22, 2026. DOI: 10.1210/clinem/dgag227.
A Case Report
[Posted 17/Nov/2026]
AUDIENCE: Emergency Medicine, Endocrinology, Internal Medicine
KEY FINDINGS: Long-term PPI use may contribute to impaired calcium homeostasis through hypomagnesemia and reduced PTH secretion or responsiveness. Clinicians should consider electrolyte disturbances in patients presenting with unexplained muscle spasms, paresthesia or QTc prolongation.
BACKGROUND: Long-term proton pump inhibitor (PPI) therapy has been associated with mineral metabolism disturbances, particularly hypomagnesemia, which can interfere with calcium regulation. This case highlights a rare but serious presentation of symptomatic hypocalcemia in a patient taking pantoprazole for several years. Springer Nature Link
DETAILS: A 54-year-old woman presented with progressive weakness, tingling sensations and painful involuntary muscle contractions. Examination revealed bilateral carpopedal spasms and positive Trousseau’s and Chvostek’s signs. ECG showed QTc prolongation. Laboratory investigations revealed severe hypocalcemia, with total calcium of 5.2 mg/dL and ionized calcium of 0.74 mmol/L. She also had mild hypomagnesemia (1.5 mg/dL), vitamin D insufficiency (18 ng/mL) and an inappropriately low parathyroid hormone level (13 pg/mL).
The patient had been self-administering pantoprazole 40 mg daily for approximately four years without regular medical reassessment. Treatment included discontinuation of pantoprazole, intravenous calcium gluconate under cardiac monitoring, magnesium and vitamin D supplementation, followed by oral calcium therapy. Neuromuscular symptoms improved within 24 hours of treatment. At one-month follow-up, the patient remained asymptomatic, with normalized calcium and magnesium levels and improved vitamin D status.
Important limitation: This single case cannot establish that pantoprazole directly caused hypocalcemia. Vitamin D insufficiency and impaired PTH response may also have contributed.
Copyright © Skyscape. All rights reserved.
Source: Khaneghahi, A., Zamani, S., Akbari, M., et al. evere symptomatic hypocalcemia with neuromuscular hyperexcitability associated with long-term pantoprazole use: a case report. International Journal of Emergency Medicine. 2026; 19:261. Published: October 6, 2026. DOI: 10.1186/s12245-026-01398-5.
KEY FINDINGS: The change from PCOS to PMOS reflects a broader understanding of the condition and its implications beyond ovarian function. The review identifies several clinically relevant considerations:
BACKGROUND: PMOS affects an estimated 10%–13% of women of reproductive age and remains underdiagnosed. Historically viewed mainly as a reproductive condition, it is now recognized as a complex endocrine and metabolic disorder with reproductive, psychological, dermatological and cardiometabolic consequences. The change in nomenclature reflects a broader understanding of the condition. The term PCOS can be misleading because the ovarian appearance typically involves arrested follicles rather than an increased number of pathological ovarian cysts. The updated terminology is intended to better represent the condition's underlying biology and its effects beyond the ovaries.
DETAILS: Insulin resistance as the central mechanism Insulin resistance is a defining feature of PMOS and is reported in 75% of lean women and 95% of overweight women when measured using euglycemic–hyperinsulinemic clamps. Unlike insulin resistance associated primarily with obesity, the condition appears to involve an intrinsic, tissue-specific defect that can occur independently of excess adiposity. Compensatory hyperinsulinemia contributes to increased ovarian and adrenal androgen production, reduced hepatic sex hormone-binding globulin (SHBG), and disrupted follicular development. These processes reinforce one another, linking metabolic dysfunction with hyperandrogenism and ovulatory abnormalities.
Diabetes and metabolic complications
A pooled analysis of 41 studies reported increased odds of impaired fasting glucose (OR 3.2), impaired glucose tolerance (OR 3.9), and type 2 diabetes (OR 2.9) in women with PMOS. Importantly, the increased diabetes risk is also observed in women without obesity. The review highlights the importance of regular glycemic surveillance. The 2023 International Evidence-Based Guideline recommends testing at least every 3 years, with more frequent assessment for women with additional risk factors, including previous gestational diabetes, family history of type 2 diabetes and elevated BMI. A 75-g oral glucose tolerance test is identified as the preferred assessment method, although practical limitations affect its accessibility. Metabolic dysfunction-associated steatotic liver disease (MASLD) is another important complication. A pooled prevalence of 43% has been reported among women with PMOS, with insulin resistance, metabolic syndrome and biochemical hyperandrogenism identified as associated risk factors.
Cardiovascular risk
The review presents evidence that cardiovascular complications emerge earlier in women with PMOS than in the general female population. The condition is associated with a 20%–70% increased risk of cardiovascular disease, depending on the population studied, and an approximately 3-fold increased risk of type 2 diabetes.
Atherogenic dyslipidemia affects 60%–70% of women with PMOS, typically involving elevated triglycerides, reduced HDL cholesterol and increased small dense LDL particles. Hypertension occurs 2–3-fold more frequently than in age-matched controls. Central obesity, chronic inflammation and endothelial dysfunction further contribute to cardiovascular risk. Population-based studies provide evidence of increased cardiovascular events, not merely an unfavourable risk-factor profile. A Danish cohort comparing 18,112 women with PMOS with 54,336 matched controls reported an increased incidence of cardiovascular disease (HR 1.71; 95% CI, 1.56–1.88). Risks were also elevated for myocardial infarction (HR 1.78) and ischemic heart disease (HR 1.73).
A Nordic population-based cohort of nearly 130,000 women reported an increased risk of cardiovascular disease (HR 1.27 [1.18; 1.36]), major adverse cardiovascular events (1.21 [1.10; 1.34]) and deep venous thrombosis (1.30 [1.27; 1.33]). Cardiovascular risk was also elevated among women with a BMI below 25 kg/m² (HR 1.40 [1.26; 1.55]). Notably, cardiovascular risk curves began to diverge at approximately 35 years of age in population-based studies, emphasizing the importance of early identification and preventive care.
Management and emerging treatment approaches
Lifestyle intervention, including structured exercise, balanced nutrition and behavioural strategies, remains the foundation of management. Metformin is recommended particularly for adults with a BMI of 25 kg/m² or higher, with benefits for insulin sensitivity and glycemic outcomes. GLP-1 receptor agonists may provide greater weight reduction than metformin, although evidence specifically in PMOS remains limited. A systematic review of 11 randomized controlled trials reported a reduction in BMI of 1.38 kg/m² (95% CI 0.38–2.39 kg/m²). These medications are contraindicated during pregnancy, and effective contraception is recommended during treatment. For severe obesity, bariatric surgery may improve weight, diabetes, hypertension, ovulation and fertility. Treatment decisions should be individualized according to metabolic risk, clinical manifestations and reproductive goals.
The review reinforces PMOS as a lifelong multisystem endocrine and metabolic disorder rather than an isolated reproductive condition. Insulin resistance and compensatory hyperinsulinemia provide an important biological link between reproductive dysfunction, type 2 diabetes and cardiovascular disease. Population-based evidence indicates that cardiovascular risk may emerge from early adulthood, including in women without obesity. The authors emphasize early diagnosis, systematic metabolic surveillance, cardiovascular risk assessment and individualized interventions as priorities for improving long-term outcomes.
The article is a review of evolving evidence, not a new clinical trial. Several therapeutic approaches remain supported by limited or low-quality evidence, and further research is needed to develop validated cardiovascular risk-prediction tools and long-term prevention strategies.
Copyright © Skyscape. All rights reserved.
Source: Forslund, M., Melin, J., Joham, A.E., et al. Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk. Journal of Internal Medicine. 2026; Published: August 30, 2026. DOI: 10.1111/joim.70156.
KEY FINDINGS: HFpEF and CKD should be considered interconnected conditions rather than isolated disorders. Traditional cardiovascular risk factors and CKD-specific pathophysiological processes contribute to heart failure risk, while the heterogeneity of HFpEF complicates clinical assessment. Phenotype-informed risk stratification may help clinicians identify high-risk patients and tailor preventive care. The review emphasizes the need to integrate kidney disease assessment into cardiovascular risk evaluation and prevention planning. s
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) frequently coexist and contribute to substantial morbidity and mortality. In patients with CKD, traditional cardiovascular risk factors combine with kidney-specific pathophysiological mechanisms to increase susceptibility to HFpEF. The clinical heterogeneity of HFpEF complicates diagnosis, risk stratification, prevention, and treatment, highlighting the need for approaches that account for the interaction between cardiac and renal disease.
DETAILS: In this Kidney Cross-Talk review, Krishnan and colleagues examine the epidemiology of HFpEF in patients with CKD, the mechanisms linking kidney dysfunction to HFpEF development, and the influence of CKD on HFpEF phenotyping. The authors discuss how identifying distinct clinical phenotypes may improve characterization of disease, support individualized management, and strengthen risk prediction. They also propose a risk-based algorithm for preventing heart failure in patients with CKD.
This is a narrative review rather than a clinical trial or meta-analysis; therefore, it does not report a single pooled treatment effect. The authors highlight the contribution of CKD-related mechanisms to HFpEF development and the importance of recognizing distinct HFpEF phenotypes to improve risk assessment and guide preventive strategies. The proposed risk-based prevention algorithm offers a framework for identifying patients with CKD who may benefit from more targeted heart failure prevention.
Copyright © Skyscape. All rights reserved.
Source: Krishnan, V., Khan, S. S., and Mehta, R. The Intersection of Heart Failure with Preserved Ejection Fraction and CKD. Clinical Journal of the American Society of Nephrology. 2026; 21(10): 1847-1855. Published: October 22, 2026. DOI: 10.2215/CJN.0000001013.
KEY FINDINGS: The STRONG-DM pilot demonstrates that integrating NT-proBNP screening with electronic clinical decision support and virtual CKM consultation is feasible in primary care and can substantially increase prescribing of therapies relevant to HF prevention. Biomarker screening also identified patients whose elevated risk was not captured by the clinical risk score alone.
The study evaluated prescribing behavior rather than reductions in incident HF, hospitalization, or mortality. Its findings therefore support the feasibility of this prevention strategy but do not establish that it improves clinical outcomes. Larger randomized trials are needed to determine whether the approach reduces the long-term burden of HF among adults with T2DM.
BACKGROUND: Adults with type 2 diabetes mellitus (T2DM) face an elevated risk of developing heart failure (HF), yet preventive cardiometabolic therapies remain underused. Identifying patients at increased risk before HF develops may provide an opportunity to initiate targeted treatment. The STRONG-DM pilot study evaluated a virtual cardio-kidney-metabolic (CKM) prevention strategy integrating clinical risk assessment, N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing, and specialist consultation to improve preventive prescribing.
DETAILS: The prospective intervention study included 545 adults with T2DM and no previous HF who received care from participating primary care physicians. The intervention combined physician education, electronic health record recommendations for NT-proBNP screening, and virtual CKM consultations for patients considered at high risk based on a WATCH-DM score of at least 12 or an NT-proBNP level of at least 125 pg/mL. New prescriptions for sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and finerenone were assessed over six months. Outcomes were compared with those of matched patients receiving usual care from nonparticipating physicians in the same practices.
Primary care physicians ordered NT-proBNP testing in 93.4% of participants, and 36.9% were classified as being at high risk for HF. NT-proBNP testing identified an additional 16.7% of patients as high risk despite their low-risk classification using the WATCH-DM score.
Compared with matched controls, patients in the intervention group were more likely to receive new prescriptions for SGLT2 inhibitors (20.3% vs 5.8%; P < .001) and finerenone (4.1% vs 0.2%; P < .001). Initiation of GLP-1 RAs did not differ significantly between groups. Overall, the intervention was associated with a threefold higher rate of initiating any of the assessed CKM therapies (incidence rate ratio, 3.03; 95% CI, 2.18-4.31; P < .001). The increase was greater among patients classified as high risk (incidence rate ratio, 5.03; 95% CI, 3.06-8.77) than among those classified as low risk (1.82; 95% CI, 1.15-2.96; interaction P = .005).
Copyright © Skyscape. All rights reserved.
Source: Subramanian, V., Patel, K. V., Suh, J. M., et al. Screening and Treatment Using a Risk-Based Approach With NT-proBNP Guidance in Diabetes Mellitus: The STRONG-DM Pilot Study. JACC: Heart Failure. 2026; 14(10): 103153. Published: October 1, 2026. DOI: 10.1016/j.jchf.2026.103153.
KEY FINDINGS: This study found that HF was associated with increased visceral adiposity, reduced muscle volume, and greater muscle fat infiltration, even when patients were compared with controls matched for BMI. The differing patterns across HF phenotypes suggest that body composition abnormalities are not uniform among patients with heart failure.
The findings indicate that BMI and conventional anthropometric measures may underestimate clinically relevant metabolic and muscular abnormalities. Advanced imaging and more consistent definitions of sarcopenia may improve characterization of these abnormalities, although further research is needed to determine their prognostic value and implications for treatment.
BACKGROUND: Heart failure (HF) is associated with metabolic and musculoskeletal abnormalities that may not be adequately captured by body mass index (BMI). Excess visceral fat, reduced skeletal muscle volume, and increased fat infiltration within muscle can coexist and may differ across HF phenotypes. This study used advanced imaging to characterize body composition in patients with HF compared with matched controls and to examine differences among HF with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF).
DETAILS: Researchers analyzed participants in the UK Biobank Imaging Study. A total of 185 individuals with HF and available ejection fraction measurements were matched in a 1:5 ratio with 925 controls matched for age, sex, and BMI. Whole-body magnetic resonance imaging (MRI) was used to quantify visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue, liver fat, thigh fat-free muscle volume, and muscle fat infiltration (MFI). Dual-energy x-ray absorptiometry (DXA) was used to measure total fat and appendicular lean mass. Personalized z-scores adjusted for sex and body size were calculated. Adverse muscle composition (AMC) was defined by the combination of low muscle volume and high muscle fat infiltration. The investigators also assessed sarcopenia using grip strength and DXA-derived lean mass criteria.
Compared with matched controls, participants with HF had significantly greater visceral adipose tissue (z-score, 0.46 ± 1.1 vs 0.07 ± 1.0; P < 0.001) and muscle fat infiltration (8.4% ± 2.3% vs 7.6% ± 2.0%; P < 0.001). Adverse muscle composition was present in 36% of participants with HF compared with 17% of controls (P < 0.001). Muscle volume was also lower in the HF group (z-score, −0.7 ± 1.0 vs −0.1 ± 0.9; P < 0.001). Body composition patterns differed across HF phenotypes. HFmrEF was associated with the highest visceral adipose tissue levels and lowest muscle volume. HFpEF showed greater overall fat and muscle fat infiltration, whereas HFrEF had the highest prevalence of adverse muscle composition and the weakest grip strength.
Despite the MRI-detected muscle abnormalities, the estimated prevalence of sarcopenia varied considerably according to the diagnostic criteria applied, highlighting inconsistencies among current definitions.
Copyright © Skyscape. All rights reserved.
Source: Butler, J., Fioretti, F., Anker, S. D., et al. Body Composition in Heart Failure: A Magnetic Resonance Imaging and Dual X-Ray Absorptiometry Assessment in the UK Biobank Study. JACC: Heart Failure. 2026; 14(10): 103242. Published: October, 2026. DOI: 10.1016/j.jchf.2026.103242.
Specialty: